Supplementary Materials

Real-world effectiveness and safety of Janus kinase 1 inhibitors for the treatment of moderate-to-severe atopic dermatitis: a single-center, prospective study in China

This file includes:

Appendix. Methods

Statistical analysis

Continuous values were reported as mean and standard deviation (SD) or median and interquartile range (IQR) based on normality and homogeneity of variance test, while categorical values were reported as percentages. Paired characteristics including SCORAD, EASI, POEM, PP-NRS, DLQI, CDLQI between baseline and week 2, week 4, week 16 or week 24 were compared by paired *t* test (comparison of IGA, serum IgE level, and TEC was conducted by wilcoxon paired signed-rank test). Unpaired *t* test was utilized to compare quantitative data between abrocitinib group vs. upadacitinib group. Chi-squared test or Fisher's exact test were utilized to analyze categorical values. Binary logistic analysis was utilized to evaluate the association between abrocitinib, upadacitinib and outcomes to adjust potential confounding factors including age and age of onset. Statistical significance was defined as $P<0.05$. All analyses were conducted using GraphPad Prism software version 9.0.1 and Statistical Package for the Social Sciences (version 24.0, SPSS Inc., Chicago, IL, USA).

Supplementary Table 1. Summary of adverse events of abrocitinib- or upadacitinib-treated patients during 24 weeks

Adverse events, n (%)	**Abrocitinib**	**Upadacitinib**
Acne	6(11.76%）	6(15.38%)
Nausea and vomiting	2(3.92%)	1(2.56%)
Herpes simplex viral infection	0	1(2.56%)
Skin and soft tissue infection	1(1.96%)	1(2.56%)
Elevated lipid levels	3(5.88%)	1(2.56%)
Elevated liver enzymes	1(1.96%)	1(2.56%)
Elevated uric acid	2(3.92%)	4(10.26%)
Increased monocyte counts	1(1.96%)	1(2.56%)
Decreased lymphocyte percentage	3(5.88%)	0
Decreased hemoglobin levels	1(1.96%)	1(2.56%)



Supplementary Fig 1. Comparison of EASI-75, EASI-90, IGA0/1, and PP-NRS4 percentages between abrocitinib and upadacitinib treatment groups. Percentages of (A)EASI-75, (B)EASI-90, (C)IGA0/1 and (D)PP-NRS4 were compared between abrocitinib and upadacitinib groups at week 2,4,16 and 24.